261 related articles for article (PubMed ID: 17617135)
1. Managing the progression of lower urinary tract symptoms/benign prostatic hyperplasia: therapeutic options for the man at risk.
Emberton M; Zinner N; Michel MC; Gittelman M; Chung MK; Madersbacher S
BJU Int; 2007 Aug; 100(2):249-53. PubMed ID: 17617135
[TBL] [Abstract][Full Text] [Related]
2. Transcriptomic analysis of benign prostatic hyperplasia identifies critical pathways in prostatic overgrowth and 5-alpha reductase inhibitor resistance.
Jin R; Forbes CM; Miller NL; Lafin J; Strand DW; Case T; Cates JM; Liu Q; Ramirez-Solano M; Mohler JL; Matusik RJ
Prostate; 2024 Apr; 84(5):441-459. PubMed ID: 38168866
[TBL] [Abstract][Full Text] [Related]
3. Silodosin in the treatment of benign prostatic hyperplasia.
Rossi M; Roumeguère T
Drug Des Devel Ther; 2010 Oct; 4():291-7. PubMed ID: 21116335
[TBL] [Abstract][Full Text] [Related]
4. Glucocorticoids are induced while dihydrotestosterone levels are suppressed in 5-alpha reductase inhibitor treated human benign prostate hyperplasia patients.
Jin R; Forbes C; Miller NL; Strand D; Case T; Cates JM; Kim HH; Wages P; Porter NA; Mantione KM; Burke S; Mohler JL; Matusik RJ
Prostate; 2022 Oct; 82(14):1378-1388. PubMed ID: 35821619
[TBL] [Abstract][Full Text] [Related]
5. Fexapotide triflutate: results of long-term safety and efficacy trials of a novel injectable therapy for symptomatic prostate enlargement.
Shore N; Tutrone R; Efros M; Bidair M; Wachs B; Kalota S; Freedman S; Bailen J; Levin R; Richardson S; Kaminetsky J; Snyder J; Shepard B; Goldberg K; Hay A; Gange S; Grunberger I
World J Urol; 2018 May; 36(5):801-809. PubMed ID: 29380128
[TBL] [Abstract][Full Text] [Related]
6. [Natural 5α-reductase inhibitors in treatment of benign prostatic hyperplasia].
Zheng RR; Ouyang QX; Liu ZY; Li LN; Yang L; Wang ZT
Zhongguo Zhong Yao Za Zhi; 2024 Feb; 49(4):858-867. PubMed ID: 38621893
[TBL] [Abstract][Full Text] [Related]
7. Postoperative medical treatment of lower urinary tract symptoms after benign prostatic hyperplasia surgery. Are we underestimating the problem?
Spivak L; Morozov A; Shpikina A; Enikeev D; Rapoport L
Curr Opin Urol; 2021 Sep; 31(5):451-455. PubMed ID: 34175875
[TBL] [Abstract][Full Text] [Related]
8. Alpha1-adrenoceptor subtypes and lower urinary tract symptoms.
Schwinn DA; Roehrborn CG
Int J Urol; 2008 Mar; 15(3):193-9. PubMed ID: 18304211
[TBL] [Abstract][Full Text] [Related]
9. Acute urinary retention in benign prostatic hyperplasia: Risk factors and current management.
Muruganandham K; Dubey D; Kapoor R
Indian J Urol; 2007 Oct; 23(4):347-53. PubMed ID: 19718286
[TBL] [Abstract][Full Text] [Related]
10. Exploring the Enigma of 5-ARIs Resistance in Benign Prostatic Hyperplasia: Paving the Path for Personalized Medicine.
Lin Z; Liu Z; Niu Y
Curr Urol Rep; 2023 Dec; 24(12):579-589. PubMed ID: 37987980
[TBL] [Abstract][Full Text] [Related]
11. Five-alpha reductase inhibitors and risk of prostate cancer among men with benign prostatic hyperplasia: A historical cohort study using primary care data.
Thakrar DB; Douglas IJ; Smeeth L; Bhaskaran K
Wellcome Open Res; 2023; 8():295. PubMed ID: 38774490
[No Abstract] [Full Text] [Related]
12. The role of the androgen receptor in prostate development and benign prostatic hyperplasia: A review.
Vickman RE; Franco OE; Moline DC; Vander Griend DJ; Thumbikat P; Hayward SW
Asian J Urol; 2020 Jul; 7(3):191-202. PubMed ID: 32742923
[TBL] [Abstract][Full Text] [Related]
13. Role of Primary Care Clinicians in the Diagnosis and Treatment of LUTS and BPH.
Kuritzky L
Rev Urol; 2004; 6 Suppl 9(Suppl 9):S53-9. PubMed ID: 16985926
[TBL] [Abstract][Full Text] [Related]
14. 5alpha-reductase: history and clinical importance.
Marks LS
Rev Urol; 2004; 6 Suppl 9(Suppl 9):S11-21. PubMed ID: 16985920
[TBL] [Abstract][Full Text] [Related]
15. Combination medical therapy for lower urinary tract symptoms and benign prostatic hyperplasia.
Roehrborn CG
Rev Urol; 2005; 7 Suppl 8(Suppl 8):S43-51. PubMed ID: 16985890
[TBL] [Abstract][Full Text] [Related]
16. Reducing the risk of benign prostatic hyperplasia progression.
Roehrborn CG
Rev Urol; 2002; 4 Suppl 5(Suppl 5):S29-38. PubMed ID: 16986063
[TBL] [Abstract][Full Text] [Related]
17. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE.
Roehrborn CG
BJU Int; 2008 Mar; 101 Suppl 3():17-21. PubMed ID: 18307681
[TBL] [Abstract][Full Text] [Related]
18. Age-related changes for the predictors of benign prostatic hyperplasia in Chinese men aged 40 years or older.
Shao WH; Zheng CF; Ge YC; Chen XR; Zhang BW; Wang GL; Zhang WD
Asian J Androl; 2023; 25(1):132-136. PubMed ID: 35532557
[TBL] [Abstract][Full Text] [Related]
19. Monopolar Transurethral Resection of Prostate for Benign Prostatic Hyperplasia in Patients With and Without Preoperative Urinary Catheterization: A Prospective Comparative Study.
Adhikari B; Shrestha A; Basnet RB; Shrestha PM; Gharti BB; Shah AK
Cureus; 2021 Jul; 13(7):e16705. PubMed ID: 34466330
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
